Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
8.88 USD +98.66% Intraday chart for Novavax, Inc. +80.12% +85.00%
12:17am Wall Street closes up ahead of inflation data RE
May. 10 News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ

Business Summary

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Number of employees: 1,543

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Vaccines
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Managers

Managers TitleAgeSince
John Jacobs CEO
 Chief Executive Officer 57 23-01-22
John Trizzino PSD
 President 64 14-03-09
James Kelly DFI
 Director of Finance/CFO 58 21-08-15
Troy Morgan CMP
 Compliance Officer - 21-04-18
Raburn Mallory CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Seth Toback CTO
 Chief Tech/Sci/R&D Officer - 20-06-30
Gale Smith CTO
 Chief Tech/Sci/R&D Officer - 03-12-31
Filip Dubovsky CTO
 Chief Tech/Sci/R&D Officer 59 20-06-16
Biegie Lee CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Silvia Taylor IRO
 Public Communications Contact - 20-06-16

Members of the board

Members of the board TitleAgeSince
Richard Rodgers BRD
 Director/Board Member 57 22-10-28
Gregg Alton BRD
 Director/Board Member 58 20-10-31
David Mott BRD
 Director/Board Member 58 20-06-15
James Young CHM
 Chairman 71 10-04-06
Margaret McGlynn BRD
 Director/Board Member 64 20-12-06
Rachel King BRD
 Director/Board Member 64 18-10-31
Richard Douglas BRD
 Director/Board Member 71 10-08-05
John Jacobs CEO
 Chief Executive Officer 57 23-01-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 141,402,844 133,395,361 ( 94.34 %) 1,000,323 ( 0.7074 %) 94.34 %

Shareholders

NameEquities%Valuation
STATE STREET CORPORATION
11.99 %
16,775,875 11.99 % 80 M $
Shah Capital Management, Inc.
7.646 %
10,700,794 7.646 % 51 M $
Shah Capital Management, Inc.
5.560 %
7,780,756 5.560 % 37 M $
Morgan Stanley Investment Management, Inc.
5.174 %
7,241,455 5.174 % 35 M $
SK BIOSCIENCE CO.,LTD.
4.644 %
6,500,000 4.644 % 31 M $
Geode Capital Management LLC
1.642 %
2,297,507 1.642 % 11 M $
Rafferty Asset Management LLC
1.152 %
1,611,840 1.152 % 8 M $
Coatue Management LLC
1.086 %
1,519,594 1.086 % 7 M $
TSP Capital Management Group LLC
0.9839 %
1,376,950 0.9839 % 7 M $
Bank of America, NA (Charlotte, North Carolina)
0.9481 %
1,326,942 0.9481 % 6 M $

Company contact information

Novavax, Inc.

700 Quince Orchard Road

20878, Gaithersburg

+240 268 2000

http://www.novavax.com
address Novavax, Inc.(NVAX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.88 USD
Average target price
17 USD
Spread / Average Target
+91.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVAVAX, INC. Stock Novavax, Inc.
+85.00% 1.24B
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. Company Novavax, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW